Compare Davita Inc (DVA) vs SPDR Gold Trust (GLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs SPDR Gold Trust — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while SPDR Gold Trust trades at $384.52 (market cap $141.59B). The key difference: SPDR Gold Trust is far larger — about 12.6× Davita Inc's market cap, and Davita Inc is trading nearer its 52-week high, SPDR Gold Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and SPDR Gold Trust for 74 Days on average.
| DVA | GLD | |
|---|---|---|
Market Cap | $11.28B | $141.59B |
Volume | 650,294 | 7,008,541 |
Sector | Health | — |
52-Week High | $240.96 | $495.90 |
52-Week Low | $103.87 | $362.32 |
Typical Hold Time | 113 Days | 74 Days |
Enterprise Value | $24.00B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
GLD is trading at $375.88, down 1.66% over the past 24 hours amid broader pressure from rising Treasury yields and a stronger U.S. dollar. The technical picture remains bearish with key support at $372 and resistance at $378. Recent news highlights gold's struggle to maintain momentum despite safe-haven demand, with weak payrolls data failing to spark a sustained rally.
The outlook for GLD remains challenged by persistent headwinds from elevated interest rates and dollar strength, though some analysts see tactical buying opportunities at current levels. Key risks include further Fed rate hikes and declining investor sentiment, while potential catalysts include geopolitical tensions and inflation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About SPDR Gold Trust
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →
